GlassScriptPhysician profile
Margarett Ellison
NPI 1871591297
$81,473.11
in general payments reported to CMS, 2019-2025
43 companies · $21K in 2025
The $21K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,073 · 2020: $1,008 · 2021: $7,452 · 2022: $20K · 2023: $28K · 2024: $2,428 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $6,468 · Food and Beverage: $3,877 · Honoraria: $3,000 · Gift: $14.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $24,124.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,260.00 |
| Travel and Lodging | $6,468.39 |
| Food and Beverage | $3,877.32 |
| Honoraria | $3,000.00 |
| Gift | $14.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $43,823.12 | 2019-2025 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $13,814.97 | 2019-2025 | Lynparza, Keytruda |
| Astrazeneca Pharmaceuticals LP | $10,625.82 | 2021-2023 | Lynparza, Tagrisso |
| Myriad Genetic Laboratories, INC. | $6,431.06 | 2020-2024 | Precisetumor, Myrisk |
| Eisai INC. | $1,888.56 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,422.26 | 2020-2025 | Jemperli, Zejula |
| Vertex Pharmaceuticals Incorporated | $783.60 | 2025 | |
| Astellas Pharma US INC | $270.08 | 2021-2025 | Veozah, Padcev |
| Abbvie INC. | $244.34 | 2021-2025 | |
| Seagen INC. | $236.13 | 2021-2024 | |
| Tesaro, INC. | $224.08 | 2019 | |
| Daiichi Sankyo INC. | $188.68 | 2021-2024 | Injectafer, Enhertu |
| Ethicon US, LLC | $138.21 | 2019-2020 | |
| Clovis Oncology, INC. | $125.88 | 2020 | |
| Mallinckrodt Enterprises LLC | $124.95 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margarett Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.